EARLY RECOGNITION AND MANAGEMENT OF OCULAR MANIFESTATIONS OF TOXIC EPIDERMAL NECROLYSIS IN A PEDIATRIC PATIENT: A CASE REPORT

This case report details the clinical course and management of toxic epidermal necrolysis (TEN) in a pediatric patient, emphasizing the significant of early use of Prokera in treating acute ocular manifestations.

This case report was conducted at Bahrain Defense Hospital, where the patient was initially seen in the emergency room and subsequently admitted to the hospital.

This case report details the clinical course and management of TEN in a pediatric patient, emphasizing the significant role of Prokera in treating acute ocular manifestations.

The final outcome demonstrated significant improvement in ocular surface healing and stabilization of conjunctival and corneal conditions. The patient’s long-term medication regimen included dorzolamide/timolol (Cosopt), moxifloxacin (Vigamox), lubrication, cyclosporine (Restasis), tacrolimus, methotrexate, folic acid, and fusidic acid ointment with hydrocortisone acetate. The patient was advised to avoid penicillins, cephalosporins, and NSAIDs due to the suspected drug-induced SJS. Ongoing follow-up visits were recommended for monitoring and prompt reporting to the ER if necessary.

This case highlights the crucial role of early intervention with Prokera in managing ocular symptoms of TEN in pediatric patients. Using Prokera alongside systemic immune suppression and supportive treatments was essential in preventing long-term eye complications. Continued research and increased clinical awareness regarding Prokera are key to improving outcomes and optimizing care strategies for pediatric TEN cases with ocular involvement.